André J. Scheen is at the Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège B-4000, Belgium; and the Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège B-4000, Belgium.
Checking for direct PDF access through Ovid
Three cardiovascular outcome trials failed to show superiority of DPP4 inhibitors compared with placebo in patients with type 2 diabetes mellitus and high cardiovascular risk, a rather disappointing finding. Now, a post hoc subgroup analysis suggests that patients treated with metformin at baseline might benefit from DPP4 inhibitors in contrast with metformin non-users.Refers to Crowley, M. J. et al. Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes. Diabetes Carehttp://dx.doi.org/10.2337/dc17-1528 (2017)